{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:36:59Z","timestamp":1782934619659,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Damietta General Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients undergoing bariatric surgery face an elevated risk of venous thromboembolism (VTE), primarily due to obesity-related hypercoagulability and changes in the pharmacokinetics of anticoagulants. The standard prophylactic dosing of enoxaparin may not be adequate for this group, leading to the consideration of higher or BMI-adjusted dosing regimens. Nevertheless, the comparative efficacy and safety of standard-dose versus higher-dose enoxaparin in the context of bariatric surgery remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis were performed following the PRISMA 2020 guidelines. Searches were conducted in PubMed, Embase, Scopus, Web of Science, and the Cochrane Library from their inception through September 30, 2025. The review included randomized controlled trials and cohort studies comparing enoxaparin 40\u00a0mg with 60\u00a0mg for postoperative venous thromboembolism (VTE) prophylaxis in bariatric surgery. Studies utilizing fixed-dose or BMI-tiered dosing strategies were considered eligible. The primary outcome assessed was the achievement of prophylactic anti-factor Xa levels. Secondary outcomes comprised mean anti-factor Xa levels, sub- and supra-prophylactic anti-factor Xa levels, VTE occurrence, bleeding incidents, mortality rates, overall complications, operative duration, and transfusion requirements. Random-effects meta-analyses were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten studies encompassing 1,276 patients (727 receiving 40\u00a0mg and 549 receiving 60\u00a0mg) were included. Enoxaparin 40\u00a0mg was associated with significantly lower mean anti-factor Xa levels compared with 60\u00a0mg (MD\u2009\u2212\u20090.08 IU\/mL; 95% CI\u2009\u2212\u20090.13 to \u2212\u20090.03). Patients receiving 40\u00a0mg had higher rates of sub-prophylactic anti-Xa levels (RR 1.35; 95% CI 1.03\u20131.77), whereas 60\u00a0mg was associated with increased supra-prophylactic levels (RR 0.25; 95% CI 0.09\u20130.70). Overall achievement of target prophylactic anti-Xa levels did not differ between doses, although once-daily 40\u00a0mg dosing was associated with reduced target attainment compared with once-daily 60\u00a0mg. No significant differences were observed in VTE, deep vein thrombosis, pulmonary embolism, bleeding, mortality, overall complications, operative duration, or transfusion requirements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although higher enoxaparin doses improved anti-factor Xa levels, this did not translate into reductions in venous thromboembolism, bleeding, or mortality, underscoring the disconnect between pharmacokinetic markers and clinical outcomes in bariatric surgery patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>PROSPERO CRDXXXXXXXXXXX.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11695-026-08765-4","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:49:38Z","timestamp":1781074178000},"page":"3914-3931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enoxaparin 40\u00a0mg Versus 60\u00a0mg for Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Systematic Review and Meta-Analysis of Pharmacologic and Clinical Outcomes"],"prefix":"10.1007","volume":"36","author":[{"given":"Mahmoud","family":"Albashier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Moqbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Omar","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan Kamal","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mahadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Hany","family":"Ezz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Omar","family":"Dakhly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya A.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosam","family":"Elghadban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"1","key":"8765_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1161\/circulationaha.107.709204","volume":"117","author":"W Ageno","year":"2008","unstructured":"Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117(1):93\u2013102. https:\/\/doi.org\/10.1161\/circulationaha.107.709204.","journal-title":"Circulation"},{"issue":"9","key":"8765_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/17474086.2019.1634542","volume":"12","author":"R Hamadi","year":"2019","unstructured":"Hamadi R, Marlow CF, Nassereddine S, Taher A, Finianos A. Bariatric venous thromboembolism prophylaxis: an update on the literature. Expert Rev Hematol. 2019;12(9):763\u201371. https:\/\/doi.org\/10.1080\/17474086.2019.1634542.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"8765_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jamcollsurg.2011.04.030","volume":"213","author":"NT Nguyen","year":"2011","unstructured":"Nguyen NT, Masoomi H, Magno CP, Nguyen XM, Laugenour K, Lane J. Trends in use of bariatric surgery, 2003\u20132008. J Am Coll Surg. 2011;213(2):261\u20136. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2011.04.030.","journal-title":"J Am Coll Surg"},{"issue":"5","key":"8765_CR4","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1007\/s11695-024-07196-3","volume":"34","author":"WA Brown","year":"2024","unstructured":"Brown WA, Liem R, Al-Sabah S, Anvari M, Boza C, Cohen RV, Ghaferi A, V\u00e5ge V, Himpens J, Kow L, et al. Metabolic Bariatric Surgery Across the IFSO Chapters: Key Insights on the Baseline Patient Demographics, Procedure Types, and Mortality from the Eighth IFSO Global Registry Report. Obes Surg. 2024;34(5):1764\u201377. https:\/\/doi.org\/10.1007\/s11695-024-07196-3.","journal-title":"Obes Surg"},{"issue":"3","key":"8765_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1067\/mcp.2002.127114","volume":"72","author":"GJ Sanderink","year":"2002","unstructured":"Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, Montay G, Boutouyrie B, Miro A. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308\u201318. https:\/\/doi.org\/10.1067\/mcp.2002.127114.","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"8765_CR6","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.thromres.2008.08.005","volume":"123","author":"NP Clark","year":"2008","unstructured":"Clark NP. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res. 2008;123(Suppl 1):S58\u201361. https:\/\/doi.org\/10.1016\/j.thromres.2008.08.005.","journal-title":"Thromb Res"},{"issue":"10","key":"8765_CR7","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1381\/096089205774859245","volume":"15","author":"GG Hamad","year":"2005","unstructured":"Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg. 2005;15(10):1368\u201374. https:\/\/doi.org\/10.1381\/096089205774859245.","journal-title":"Obes Surg"},{"key":"8765_CR8","doi-asserted-by":"publisher","unstructured":"Arcelus JI, Gouin-Thibault I, Samama CM. European guidelines on peri-operative venous thromboembolism prophylaxis: first update.: Chap. 10: Surgery in the obese patient. Eur J Anaesthesiol | EJA. 2024;41(8):622\u20136. https:\/\/doi.org\/10.1097\/eja.0000000000002000","DOI":"10.1097\/eja.0000000000002000"},{"key":"8765_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2147\/vhrm.S73799","volume":"11","author":"MA Bartlett","year":"2015","unstructured":"Bartlett MA, Mauck KF, Daniels PR. Prevention of venous thromboembolism in patients undergoing bariatric surgery. Vasc Health Risk Manag. 2015;11:461\u201377. https:\/\/doi.org\/10.2147\/vhrm.S73799.","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"8765_CR10","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s11695-021-05825-9","volume":"32","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Ye Z, Lin J, Zhang Z, Tian P, Zhang Z, Zhang P, Cui X. Efficacy and Safety of Pharmacoprophylaxis for Venous Thromboembolism in Patients Undergoing Bariatric Surgery: a Systematic Review and Meta-analysis. Obes Surg. 2022;32(5):1701\u201318. https:\/\/doi.org\/10.1007\/s11695-021-05825-9.","journal-title":"Obes Surg"},{"issue":"1","key":"8765_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5045\/br.2020.55.1.44","volume":"55","author":"FM Almarshad","year":"2020","unstructured":"Almarshad FM, Almegren M, Alshuaibi T, Alobaodi N, Almutawa A, Basunbl H, AlGahtani F. Al Rawahi B: Thromboprophylaxis after bariatric surgery. Blood Res. 2020;55(1):44\u20138. https:\/\/doi.org\/10.5045\/br.2020.55.1.44.","journal-title":"Blood Res"},{"issue":"7","key":"8765_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11695-007-9382-x","volume":"18","author":"P Ojo","year":"2008","unstructured":"Ojo P, Asiyanbola B, Valin E, Reinhold R. Post discharge prophylactic anticoagulation in gastric bypass patient-how safe? Obes Surg. 2008;18(7):791\u20136. https:\/\/doi.org\/10.1007\/s11695-007-9382-x.","journal-title":"Obes Surg"},{"issue":"11","key":"8765_CR13","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1007\/s00464-008-9997-6","volume":"22","author":"EP Simone","year":"2008","unstructured":"Simone EP, Madan AK, Tichansky DS, Kuhl DA, Lee MD. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc. 2008;22(11):2392\u20135. https:\/\/doi.org\/10.1007\/s00464-008-9997-6.","journal-title":"Surg Endosc"},{"issue":"8","key":"8765_CR14","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1007\/s11695-025-07986-3","volume":"35","author":"B O\u2019Connor","year":"2025","unstructured":"O\u2019Connor B, Meister K, Fellner A, Isaacs T. Analyzing the Adequacy of BMI-Tiered Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in the Bariatric Surgery Population Based on Anti-Factor Xa Assay Data. Obes Surg. 2025;35(8):2998\u20133005. https:\/\/doi.org\/10.1007\/s11695-025-07986-3.","journal-title":"Obes Surg"},{"issue":"3","key":"8765_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s11695-021-05875-z","volume":"32","author":"J Wagner","year":"2022","unstructured":"Wagner J, Wruck H, Lautenbach A, von Kroge P, Wolter S, Mann O, Izbicki J, Dupr\u00e9e A. Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis. Obes Surg. 2022;32(3):861\u20137. https:\/\/doi.org\/10.1007\/s11695-021-05875-z.","journal-title":"Obes Surg"},{"issue":"4","key":"8765_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s11239-024-02951-w","volume":"57","author":"MR Chilbert","year":"2024","unstructured":"Chilbert MR, Zammit K, Ahmed U, Devlin A, Radparvar S, Schuler A, Woodruff AE. A systematic review of therapeutic enoxaparin dosing in obesity. J Thromb Thrombolysis. 2024;57(4):587\u201397. https:\/\/doi.org\/10.1007\/s11239-024-02951-w.","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"8765_CR17","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.4081\/hr.2015.5844","volume":"7","author":"MY Wei","year":"2015","unstructured":"Wei MY, Ward SM. The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis. Hematol Rep. 2015;7(4):5844. https:\/\/doi.org\/10.4081\/hr.2015.5844.","journal-title":"Hematol Rep"},{"key":"8765_CR18","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"10","key":"8765_CR19","doi-asserted-by":"publisher","first-page":"Ed000142","DOI":"10.1002\/14651858.Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):Ed000142. https:\/\/doi.org\/10.1002\/14651858.Ed000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"8765_CR20","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5195\/jmla.2021.1260","volume":"109","author":"T Gotschall","year":"2021","unstructured":"Gotschall T. EndNote 20 desktop version. J Med Libr Association: JMLA. 2021;109(3):520\u20132. https:\/\/doi.org\/10.5195\/jmla.2021.1260.","journal-title":"J Med Libr Association: JMLA"},{"issue":"1","key":"8765_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst reviews. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst reviews"},{"issue":"2 Suppl","key":"8765_CR22","doi-asserted-by":"publisher","first-page":"eS326","DOI":"10.1378\/chest.11-2298","volume":"141","author":"JD Douketis","year":"2012","unstructured":"Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):eS326\u2013e350. https:\/\/doi.org\/10.1378\/chest.11-2298.","journal-title":"Chest"},{"key":"8765_CR23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Res ed). 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ (Clinical Res ed)"},{"key":"8765_CR24","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clinical Res ed). 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"1","key":"8765_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA. JPT <>Higgins 2021 Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res synthesis methods 12 1 55\u201361 https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res synthesis methods"},{"key":"8765_CR26","unstructured":"R: A language and environment for statistical computing Team RC. 2023. Available at: https:\/\/www.R-project.org\/"},{"issue":"7584","key":"8765_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/bmj.39057.406644.68","volume":"334","author":"J Fletcher","year":"2007","unstructured":"Fletcher J. What is heterogeneity and is it important? BMJ (Clinical Res ed). 2007;334(7584):94\u20136. https:\/\/doi.org\/10.1136\/bmj.39057.406644.68.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"7414","key":"8765_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Res ed). 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"3","key":"8765_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/xeb.0000000000000065","volume":"13","author":"C Tufanaru","year":"2015","unstructured":"Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc. 2015;13(3):196\u2013207. https:\/\/doi.org\/10.1097\/xeb.0000000000000065.","journal-title":"Int J Evid Based Healthc"},{"issue":"5","key":"8765_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.soard.2007.11.010","volume":"4","author":"MJ Borkgren-Okonek","year":"2008","unstructured":"Borkgren-Okonek MJ, Hart RW, Pantano JE, Rantis PC, Guske PJ, Kane JM, Gordon N, Sambol NC. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis. 2008;4(5):625\u201331. https:\/\/doi.org\/10.1016\/j.soard.2007.11.010.","journal-title":"Surg Obes Relat Dis"},{"issue":"10","key":"8765_CR31","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.soard.2017.07.027","volume":"13","author":"S Gelikas","year":"2017","unstructured":"Gelikas S, Eldar SM, Lahat G. Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin. Surg Obes Relat diseases: official J Am Soc Bariatr Surg. 2017;13(10):1753\u20139. https:\/\/doi.org\/10.1016\/j.soard.2017.07.027.","journal-title":"Surg Obes Relat diseases: official J Am Soc Bariatr Surg"},{"issue":"1","key":"8765_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.soard.2020.08.016","volume":"17","author":"LA Karas","year":"2021","unstructured":"Karas LA, Nor Hanipah Z, Cetin D, Schauer PR, Brethauer SA, Daigle CR, Aminian A. Assessment of empiric body mass index-based thromboprophylactic dosing of enoxaparin after bariatric surgery: evidence for dosage adjustment using anti-factor Xa in high-risk patients. Surg Obes Relat diseases: official J Am Soc Bariatr Surg. 2021;17(1):153\u201360. https:\/\/doi.org\/10.1016\/j.soard.2020.08.016.","journal-title":"Surg Obes Relat diseases: official J Am Soc Bariatr Surg"},{"issue":"7","key":"8765_CR33","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.asjsur.2024.02.095","volume":"47","author":"K Kongsawat","year":"2024","unstructured":"Kongsawat K, Chaivanijchaya K, Pakul F, Joradol S, Kachornvitaya P, Boonchaya-Anant P, Udomsawaengsup S. Comparison of enoxaparin 40\u00a0mg versus 60\u00a0mg dosage for venous thromboprophylaxis in patients undergoing bariatric surgery: A randomized controlled trial. Asian J Surg. 2024;47(7):2985\u201390. https:\/\/doi.org\/10.1016\/j.asjsur.2024.02.095.","journal-title":"Asian J Surg"},{"issue":"3","key":"8765_CR34","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.soard.2015.08.505","volume":"12","author":"A Steib","year":"2016","unstructured":"Steib A, Degirmenci SE, Junke E, Asehnoune K, Figier M, Pericard C, Rohr S, Letessier E, Brunaud L, Vix M, et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surg Obes Relat diseases: official J Am Soc Bariatr Surg. 2016;12(3):613\u201321. https:\/\/doi.org\/10.1016\/j.soard.2015.08.505.","journal-title":"Surg Obes Relat diseases: official J Am Soc Bariatr Surg"},{"issue":"5","key":"8765_CR35","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1007\/s11695-020-04383-w","volume":"30","author":"C Stier","year":"2020","unstructured":"Stier C, Koschker AC, Stier R, Sosnierz A, Chiappetta S. Are We Missing Treatment Standards for Thromboprophylaxis of the Obese and Super-Obese Patient Population? A Prospective Systematic Cohort Study. Obes Surg. 2020;30(5):1704\u201311. https:\/\/doi.org\/10.1007\/s11695-020-04383-w.","journal-title":"Obes Surg"},{"issue":"2","key":"8765_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s11239-016-1363-2","volume":"42","author":"EA Nutescu","year":"2016","unstructured":"Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;42(2):296\u2013311. https:\/\/doi.org\/10.1007\/s11239-016-1363-2.","journal-title":"J Thromb Thrombolysis"},{"issue":"16","key":"8765_CR37","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.2106\/jbjs.20.02250","volume":"103","author":"JR Lieberman","year":"2021","unstructured":"Lieberman JR, Bell JA. Venous Thromboembolic Prophylaxis After Total Hip and Knee Arthroplasty. J bone joint Surg Am volume. 2021;103(16):1556\u201364. https:\/\/doi.org\/10.2106\/jbjs.20.02250.","journal-title":"J bone joint Surg Am volume"},{"issue":"5","key":"8765_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/21548331.2020.1788893","volume":"48","author":"YS Segon","year":"2020","unstructured":"Segon YS, Summey RD, Slawski B, Kaatz S. Surgical venous thromboembolism prophylaxis: clinical practice update. Hosp Pract (1995). 2020;48(5):248\u201357. https:\/\/doi.org\/10.1080\/21548331.2020.1788893.","journal-title":"Hosp Pract (1995)"},{"key":"8765_CR39","doi-asserted-by":"publisher","unstructured":"Pastori D, Cormaci VM, Marucci S, Franchino G, Del Sole F, Capozza A, Fallarino A, Corso C, Valeriani E, Menichelli D, et al. A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology. Int J Mol Sci. 2023;24(4). https:\/\/doi.org\/10.3390\/ijms24043169.","DOI":"10.3390\/ijms24043169"},{"issue":"2","key":"8765_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11695-007-9381-y","volume":"18","author":"BO Rowan","year":"2008","unstructured":"Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg. 2008;18(2):162\u20136. https:\/\/doi.org\/10.1007\/s11695-007-9381-y.","journal-title":"Obes Surg"},{"issue":"6","key":"8765_CR41","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1345\/aph.1L194","volume":"43","author":"EA Nutescu","year":"2009","unstructured":"Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Annals pharmacotherapy. 2009;43(6):1064\u201383. https:\/\/doi.org\/10.1345\/aph.1L194.","journal-title":"Annals pharmacotherapy"},{"issue":"1","key":"8765_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00068-025-02768-z","volume":"51","author":"A Kloub","year":"2025","unstructured":"Kloub A, Alaieb A, Kanbar A, Abumusa S, Alishaq F, Hinawi Y, Khan NA, Asim M, Abulkhair T, El-Menyar A, et al. Anti-xa guided enoxaparin thromboprophylaxis is associated with less thromboembolism than fixed dose dalteparin in trauma patients admitted to intensive care. Eur J trauma Emerg surgery: official publication Eur Trauma Soc. 2025;51(1):97. https:\/\/doi.org\/10.1007\/s00068-025-02768-z.","journal-title":"Eur J trauma Emerg surgery: official publication Eur Trauma Soc"},{"issue":"2","key":"8765_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315\u201352. https:\/\/doi.org\/10.1016\/j.chest.2015.11.026.","journal-title":"Chest"},{"issue":"22","key":"8765_CR44","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","volume":"2","author":"DM Witt","year":"2018","unstructured":"Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, Shehab N, Mock J, Myers T, Dentali F, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257\u201391. https:\/\/doi.org\/10.1182\/bloodadvances.2018024893.","journal-title":"Blood Adv"},{"issue":"3","key":"8765_CR45","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2125.2004.02253.x","volume":"59","author":"B Green","year":"2005","unstructured":"Green B, Greenwood M, Saltissi D, Westhuyzen J, Kluver L, Rowell J, Atherton J. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol. 2005;59(3):281\u201390. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02253.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"8765_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00007691-200406000-00015","volume":"26","author":"JS Hulot","year":"2004","unstructured":"Hulot JS, Vantelon C, Urien S, Bouzamondo A, Mah\u00e9 I, Ankri A, Montalescot G, Lechat P. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. Ther Drug Monit. 2004;26(3):305\u201310. https:\/\/doi.org\/10.1097\/00007691-200406000-00015.","journal-title":"Ther Drug Monit"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08765-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11695-026-08765-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08765-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:48:47Z","timestamp":1782928127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11695-026-08765-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8765"],"URL":"https:\/\/doi.org\/10.1007\/s11695-026-08765-4","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is a systematic review and meta-analysis of previously published studies. It does not include any new studies involving human participants or animals conducted by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}